QuanDx is an innovation leader in molecular diagnostics. Specializing in the development and commercialization of novel diagnostic tools, QuanDx’s products deliver personalized medicine to clinical and research laboratories worldwide.
QuanDx’s patented Yin-Yang Probe (Trademark) technology combines cutting-edge technology with ease of use to provide the best available diagnostic and prognostic information for hematological and solid tumor cancers, as well as a number of infectious diseases.
In addition to its proprietary diagnostics line, QuanDx offers state of the art instruments for PCR applications and nucleic acid extraction.
Founded in 2012, QuanDx was launched with a vision to develop and commercialize innovative and unique diagnostic assays that could be used in clinical and research laboratories worldwide. Since then, QuanDx has grown quickly, and has delivered on the promise of personalized medicine through the development and launch of cutting-edge diagnostic technologies that are faster, simpler, and more cost-effective than other tests on the market.
QuanDx is located in San Jose (San Francisco Bay Area), California, where the company benefits from being in the heart of the Bay Area’s biotech industry.
To date, QuanDx has built a diverse portfolio of tests for hematological and solid tumor cancers, including leukemia, and lung cancer. The company also offers unique testing capabilities for infectious diseases ranging from HPV to tuberculosis and MRSA.
QuanDx’s core business is the development of novel technologies and the commercialization of personalized medicine products. These include diagnostic and prognostic tests, along with research tools and companion diagnostics.
Our first commercial product lines comprise of Q-Fusion leukemia screening kits, AML/ALL leukemia screening kits, BCR-ABL P210/P190 One-tube Quant kits. The ability to detect cancer specific fusion genes is important not only in cancer research, but also increasingly in clinical settings to ensure that correct diagnosis is made and the optimal personalised treatment is chosen. It is the objective of QuanDx to offer a simpler and cost-effective solution for the detection of these important fusion genes.